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ABSTRACT 
Abstract: A simple, precise and economical UV-spectrophotometric method has been developed for the estimation of Olmutinib from bulk. Two 
methods were developed First method (A) applied was area under curve (AUC) in which the area was integrated in wavelength from 262-
272nm. Second method (B) was first order derivative spectrometric method. In this method absorbance at λmin=256.57nm, λmax=282.83nm 
and zero cross=267.68nm was measured. Calibration curves were plotted for the method by using instrumental response at selected 
wavelength and concentration of analyte in the solution. In both the methods, linearity was observed in the concentration range of 2-12µg/ml 
at the λmax=267.68nm. Accuracy and precision studies were carried out and results were satisfactorily obtained. The drug at each of the 80 %, 
100 % and 120 % levels showed good recoveries that is in the range of 98.00 to 99.00% for both methods, hence it could be said that the 
method was accurate. Limit of detection (LOD) and limit of quantitation (LOQ) were determined for the method. The method was validated as 
per International Conference on Harmonization. All validation parameters were within the acceptable limit. The developed method was 
successfully applied to estimate the amount of Olmutinib in pharmaceutical formulation. 
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INTRODUCTION: 
Epidermal growth factor binds with high affinity to 
epidermal growth factor receptor (EGFR) upon cell surface, 
activates the intrinsic protein-tyrosine kinase activity of 
receptor, initiating signal transduction cascade results in 
various biochemical changes in the cell - rises calcium levels, 
increased protein synthesis and increases expression of 
certain genes. Eg.gene of EGFR leads to DNA synthesis and 
cell proliferation. Mutations of EGFR expressions or activity 
results are in cancer.1 
Olmutinib N-(3-((2-((4-(4-methylpiperazin-1-
yl)phenyl)aminao)thieno[3,2-d]pyrimidin-4-
yl)oxy)phenyl)acrylamide. 
Olmutinib is an oral epidermal growth factor receptor 
tyrosine kinase inhibitor (EGFR TKI) of third generation 
which is being developed by Boehringer Ingelheim and 
Hanmi Pharmaceutical Co. Ltd to treat non-small-cell lung 
cancer (NSCLC). Olmutinib binds covalently and inhibits 
activating EGFR mutations and overcoming 
T790Mresistance mutation (mutation of epidermal growth 
factor receptor).2, 3 
In the present study, we developed a novel analytical 
method and validation of first derivative method for 
Olmutinib in bulk using UV spectroscopy. 
Literature survey reveals that a few spectrophotometric, RP-
HPLC methods are reported for the estimation of Olmutinib 
in combination with other drugs. 4 
 
Fig 01: Chemical Structure of Olmutinib 
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MATERIALS AND METHODS: 
The Olmutinib was kindly supplied as a gift sample by Mylan 
laboratories pvt.ltd., Hyderabad (India). All rest of chemicals 
used were of HPLC grade. A double beam UV-Visible 
spectrophotometer, (UV 1800, Shimadzu limited, Japan) 
having two matched cells with 1cm light path. A citizen 
analytical balance (Sartorius) was used for weighing the 
bulk sample. 
Preparation of standard stock solutions: 
Standard solution of Olmutinib was prepared by transferring 
accurately weighed 10 mg of drug into a 100ml volumetric 
flask and the volume was made up to 100ml using methanol 
as a solvent to get the concentration of 100μg/ml. 
Selection of wavelength for analysis of Olmutinib: 
Accurately pipette out 1.0 mL volume of standard stock 
solution of Olmutinib was transfer into a 10 mL volumetric 
flask, diluted up to a mark with methanol to give 
concentration of 10 μg/ml. The resulting solution was 
scanned in the UV range (200–400 nm) using Shimadzu UV-
VIS spectrophotometer instrument. The maximum 
absorbance of solution was measured at the wavelength 
267.68nm (Figure 2). 
Preparation of calibration curve: 
From the standard stock solution fresh aliquots were pipette 
out and suitably diluted with methanol to get final 
concentration in the range of 2-12 (μg/ml). The solutions 
were scanned under 200-400 nm wavelength range and a 
sharp peak was obtained at 267.68nm (figure 2). Calibration 
curve was plotted by taking absorbance on y-axis and 
concentration of solution on x-axis (figure 03 and 04). For 
both the methods A and B. The drug follows linearity in the 
concentration range 2-12μg/mL with a correlation 
coefficient of Method A value (R2)0.999and Method B value 
(R2) 0.997. 
 
Fig 02: Determination of Cmax of Olmutinib std. stock 
solution 
 
Fig 03: Calibration curve AUC of Olmutinib 
 
Fig 04: Calibration curve First order derivative of 
Olmutinib 
 
Fig 05: Overlay of Olmutinib showing linearity as 
increasing concentration. 
Area under curve (Method A): 
In area under curve method involves to calculation of 
integrated value of absorbance with selected wavelength. 
Area calculation calculated in bounded by the curve and 
horizontal axis. Horizontal axis represent baseline. Where, α 
is area of bounded portion by curve data and a straight line 
connecting the starting and end point and β is the area of 
portion bounded by straight line connecting starting and end 
point on curve data and horizontal axis, λ1and λ2 are wave 
length showing starting and end point from figure 6. In this 
AUC method area was integrated between the wavelength 
ranges from 262-272nm (figure 6). Also, calibration curves 
of Olmutinib was prepared in various concentration ranges 
i.e. 2-12µg/mL at their respective AUC range.5,6 
Area calculation (α + β) =
  
  
 Adλ
y = 0.0939x - 0.0113 
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Fig 06: Area under curve graph of 10µg/mL Olmutinib 
 
First Order Derivatives Spectrophotometry (Method B): 
In this method solution of Olmutinib (2-12 µg/ml) were 
prepared by appropriate dilution of standard stock solution 
and scanned in the spectrum mode from 400 nm to 200 nm. 
The absorption spectra obtained were derivatised from first 
fourth order. First order derivative spectra were selected for 
analysis of drug. From spectra of drug the absorbance was 
measured at λmax=2582.83 nm, λmin=256.57 nm and zero 
cross =267.68 nm, amplitude difference (dA) with respect to 
wavelength difference (dλ) was measured for the respective 
concentration of standard and was plotted against 
concentrations and regression equation was calculated.7, 8
 
 
Fig 07: First Order Derivative spectra of Olmutinib 
 
Validation of the developed method: 
The objective of validation of analytical procedure is to 
demonstrate whether the procedure is suitable for its 
intended purpose. The proposed method was validated for 
various parameters such as Linearity, Accuracy, Precision, 
Limit of detection (LOD) and Limit of Quantitation (LOQ) 
according to ICH Q2 (R1) guideline.10, 11
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Table 01: Linearity results of Olmutinib in methanol 
Concentration 
(µg/ml) 
Method A 
(Area under curve) 
Method B 
(First order derivative) 
2 0.1723 0.00523 
4 0.3655 0.0105 
6 0.5534 0.0175 
8 0.7430 0.0250 
10 0.93151 0.0310 
12 1.10882 0.0405 
 
Table 02: Result of Precision 
Precision Method A (%RSD) Method B (% RSD) 
Repeatability 0.368 0.375 
Intraday 0.546 0.548 
Interday 0.784 0.872 
 
Linearity: 
Fresh aliquots were prepared from the stock solution 
(100μg/ml) in different concentrations. The samples were 
scanned in UV-visible spectrophotometer against reagent 
blank. It was found that the selected drug shows linearity 
between the 2-12μg/ml (Table 01) and fig 05. 
Repeatability: 
The precision of the method was checked by repeatedly 
injecting (n=6) standard solutions of olmutinib (10μg/mL). 
Area under curve of each of these solutions was measured in 
the range of 262-272nm. Percentage relative standard 
deviation (%RSD) was calculated (Table 2). 
In first order Spectrophotometry derivative method 
concentration of the solution was determined by measuring 
absorbance at λmin= 282.83nm, λmax=256.57nm and zero 
cross=267.68nm.  
Intermediate precision (reproducibility): 
The intra-day and inter-day precision of the proposed 
method was determined by analysing the corresponding 
responses 3 times on the same day and on 3 different days 
over a period of 1 week for 3 different concentrations of 
standard solutions of olmutinib(6, 8 and 10μg/mL).The 
results were reported in terms of relative standard deviation 
(%RSD). The results were tabulated in (Table 2). 
Accuracy (Recovery studies): 
The accuracy for the analytical procedure was determined at 
80%, 100% and 120% levels of standard solution. Area 
under curve was measured in the range of 262-272nmalso 
first derivative measured in the range 256.57-282.83nm and 
results were expressed in terms of % recoveries. Three 
determinations at each level were performed and % RSD 
was calculated. The results were tabulated in (Table 3).
 
Table 03: Recovery Study of Olmutinib 
Accuracy level Method A 
Mean % recovery 
 
%RSD 
Method B 
Mean % recovery 
 
%RSD 
80% 98.03 0.630 99.09 0.825 
100% 99.06 0.760 98.08 0.745 
120% 98.29 0.648 98.25 0.798 
 
Table 04: LOD and LOQ of Olmutinib 
Method Method A Method B 
LOD 0.3786 0.4958 
LOQ 1.0523 1.7525 
 
Limit of detection and Limit of Quantitation: 
The objective of validation of analytical procedure is to 
demonstrate whether the procedure is suitable for its 
intended purpose. The proposed method was validated for 
various parameters such as Linearity, Accuracy, Precision, 
Limit of detection (LOD) and Limit of Quantitation (LOQ) 
according to ICH Q2 (R1) guideline. (Table 4) 
 
RESULT AND DISCUSSION: 
In spectroscopic technique was developed simple and 
specific method for the determination of Olmutinib in bulk 
form. The generated regression equations were, 
Method A - ∫  
   
   
dλ0.093x + 0.011 R2 = 0.999 
Method B- ∫          
   
   
x +0.0029 R2= 0.997 
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Where ∫  
   
   
dλ is area under curve between 262-272 nm, 
  
  
is amplitude difference, x is concentration and R2 is 
correlation coefficient. The R2 values were 0.999 and 0.997 
for Method A and B respectively indicated that developed 
methods were linear. The proposed methods were found to 
be precise as % RSD values for intraday as well as Interday 
precision were satisfactory. The drug at each of the 80 %, 
100 % and 120 % levels showed good recoveries that is in 
the range of 98.00to 99.00% for both methods, hence it 
could be said that these methods were accurate. The LOD 
and LOQ were calculated as 0.3786μg/ml and 1.0523μg/ml 
for method A and 0.4958μg/ml and 1.7525μg/ml for method 
B respectively. Thus, the developed method is found to be 
robust and rugged which can be applied as a rapid tool for 
routine analysis of olmutinib in the bulk and in the 
pharmaceutical dosage form. The validation parameters for 
method A and method B are summarized in Table 05.
 
Table No. 05: Optical Parameters/ Summary of Olmutinib 
Parameter Result for Method A Result for Method B 
Range  262-272 256.57-282.83 
Linearity range  2-12 (µg/mL) 2-12 (µg/mL) 
Standard regression equation  0.093x+0.011 0.002x+0.0029 
Correlation coefficient (R2) 0.9997 0.994 
Repeatability  0.368 0.375 
Intraday  0.546 0.548 
Interday  0.784 0.872 
Accuracy (Mean % Recovery) 99.06 99.09 
LOD 0.3786 0.4958 
LOQ 1.0523 1.7525 
 
CONCLUSION: 
From the results and discussion, two spectrophotometric 
methods were developed and validated as per ICH 
guidelines Q2 (R1). In this paper described for the 
determination of Olmutinib in bulk is simple, sensitive and 
reproducible. The proposed methods can be successfully 
applied for Olmutinib without any interference in quality 
control. 
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